Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.

Pharmacogenomics - 1 Dec 2021

Makarem Yasmine S, Hareedy Mohammad Salem, Hassanien Manal, Ahmed Esraa A, Hetta Helal F, Mohamed Alaa Aa

Abstract excerpt

Introduction: Leflunomide is one of the commonly used drugs in treatment of rheumatoid arthritis (RA), which on administration is converted into its active metabolite teriflunomide. Aim: Our aim is to evaluate the frequencies of dihydrooroate dehydrogenase (DHODH) (rs3213422), ABCG2 (rs2231142) and CYP2C19 (rs4244285) allele distribution among patients receiving leflunomide for RA and their possible impact on...

Read the complete abstract on PubMed

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid
Share to ATP Binding Cassette Transporter, Subfamily G, Member 2
Share to Cytochrome P-450 CYP2C19
Share to Gene Frequency
Share to Neoplasm Proteins
Share to Pharmacogenetics
Share to Young Adult

Source

Identifiers

PMID: 34747629
DOI: 10.2217/pgs-2020-0146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.PMID 34747629Read ↗

The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.Semantic proximity Read ↗

Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.Semantic proximity Read ↗

Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.Semantic proximity Read ↗

Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.Semantic proximity Read ↗

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.Semantic proximity Read ↗

Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritisSemantic proximity Read ↗

Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patientsSemantic proximity Read ↗

Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.Semantic proximity Read ↗

The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.Semantic proximity Read ↗

Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.Semantic proximity Read ↗

Genetic polymorphisms associated with therapeutic response and adverse effects to methotrexate in Taiwanese patients with rheumatoid arthritis: a real-world, hospital-based study.Semantic proximity Read ↗

Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.